Free registration required to read the following article.
Why I am Encouraged by Data on NASH Management From the 2016 Boston Hepatology Meeting
Brent A. Neuschwander-Tetri MD - 3/10/2017
The 2016 hepatology meeting in Boston brought us encouraging news on many fronts. The progress towards eradicating chronic hepatitis C virus (HCV) infection over the past 3-4 years has been nothing short of remarkable, and I look forward to the day when we will begin to see similar results in clinical trials for NASH.
However, the treatment of NASH has challenges not seen in patients with HCV infection. Patients likely exhibit the disease phenotype that we label as NASH through a variety of genetic, epigenetic, and environmental reasons, and thus, I don’t expect that any single treatment will work for all patients. Moreover, diagnosing NASH is much more complex than measuring viral titers in the blood.